Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cichorium intybus or N-acetylcysteine versus placebo for fingolimod-associated liver complications in multiple sclerosis
IRCT20120215009014N410Phase 3Completed
- Sponsor
- Hamadan University of Medical Sciences
- Start
- Dec 2021
- Modality
- Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of cichorium intybus extract, acetylcysteine, fingolimod and Placebo-COD Research Private Ltd in multiple sclerosis (MS) (3 arms), sponsored by Hamadan University of Medical Sciences. Primary endpoints: Serum alanine aminotransferase, Serum aspartate aminotransferase and 1 more. Started Dec 2021; status: completed.
02
Drugs
cichorium intybus extractacetylcysteinefingolimodPlacebo-COD Research Private Ltd
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on IRCT20120215009014N410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20120215009014N410.